| William D Morris, MD | |
|
2520 Cherry Ave, Bremerton, WA 98310-4229 | |
| (360) 377-3911 | |
| Not Available |
| Full Name | William D Morris |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 26 Years |
| Location | 2520 Cherry Ave, Bremerton, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922030949 | NPI | - | NPPES |
| 8322281 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | MD00041420 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Harrison Medical Center | Bremerton, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| West Sound Emergency Physicians Pllc | 9234133703 | 32 |
News Archive
Penn State College of Medicine researchers recently were awarded a five-year, $7 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to conduct a series of studies on human circulation.
The department of Intensive Care of the Radboud university medical center in Nijmegen, the Netherlands, has developed a unique communication app for adult and pediatric ICU patients, who cannot speak due to an intubation, being on a ventilator or breathing through a tracheostoma.
Individuals with disrupting mutations in the BRCA1 gene are known to be at substantially increased risk of breast cancer throughout their lives. Now, discoveries from an international research team led by Mayo Clinic researchers show that some of those persons may possess additional genetic variants that modify their risk. These new findings enhancing individualized medicine appear in the current Nature Genetics.
PTC Therapeutics, Inc. today announced that it has commenced a rolling submission of a New Drug Application to the United States Food and Drug Administration for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.
› Verified 1 days ago
| Entity Name | West Sound Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568489243 PECOS PAC ID: 9234133703 Enrollment ID: O20060914000454 |
News Archive
Penn State College of Medicine researchers recently were awarded a five-year, $7 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to conduct a series of studies on human circulation.
The department of Intensive Care of the Radboud university medical center in Nijmegen, the Netherlands, has developed a unique communication app for adult and pediatric ICU patients, who cannot speak due to an intubation, being on a ventilator or breathing through a tracheostoma.
Individuals with disrupting mutations in the BRCA1 gene are known to be at substantially increased risk of breast cancer throughout their lives. Now, discoveries from an international research team led by Mayo Clinic researchers show that some of those persons may possess additional genetic variants that modify their risk. These new findings enhancing individualized medicine appear in the current Nature Genetics.
PTC Therapeutics, Inc. today announced that it has commenced a rolling submission of a New Drug Application to the United States Food and Drug Administration for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William D Morris, MD 2520 Cherry Ave, Bremerton, WA 98310-4229 Ph: () - | William D Morris, MD 2520 Cherry Ave, Bremerton, WA 98310-4229 Ph: (360) 377-3911 |
News Archive
Penn State College of Medicine researchers recently were awarded a five-year, $7 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to conduct a series of studies on human circulation.
The department of Intensive Care of the Radboud university medical center in Nijmegen, the Netherlands, has developed a unique communication app for adult and pediatric ICU patients, who cannot speak due to an intubation, being on a ventilator or breathing through a tracheostoma.
Individuals with disrupting mutations in the BRCA1 gene are known to be at substantially increased risk of breast cancer throughout their lives. Now, discoveries from an international research team led by Mayo Clinic researchers show that some of those persons may possess additional genetic variants that modify their risk. These new findings enhancing individualized medicine appear in the current Nature Genetics.
PTC Therapeutics, Inc. today announced that it has commenced a rolling submission of a New Drug Application to the United States Food and Drug Administration for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.
› Verified 1 days ago
Glen Carlson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2520 Cherry Ave, Bremerton, WA 98310 Phone: 360-377-3911 | |
Dr. William Byrne Cogar, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Boone Rd, Bremerton, WA 98312 Phone: 360-475-4000 | |
William M Roberts, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Boone Rd, Bremerton, WA 98312 Phone: 360-475-4426 Fax: 360-475-4344 | |
Bernard Greenfeld, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1651 Ne Bentley Dr, Bremerton, WA 98311 Phone: 360-782-3400 Fax: 360-782-3440 | |
Martin A. Bennett, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2520 Cherry Ave, Bremerton, WA 98310 Phone: 360-377-3911 | |
Dr. Randy L Baldwin, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Boone Rd, Bremerton, WA 98312 Phone: 360-475-4426 Fax: 360-475-4344 | |
Dr. Paul Arthur Dutky, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3914 Nw Fairway Ln, Bremerton, WA 98312 Phone: 360-479-2683 Fax: 360-479-2683 |